Xtandi 80 MG tablet 60S
Ended Awarded
- Contract number
- SPE2DB25FZQ13
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $4,170
Award facts
- Contract value 100% obligated
- $4,169.59 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $4,169.59 to DMS Pharmaceutical Group Inc. for XTANDI 80 mg tablets (60-count units) with an ultimate completion date of September 9, 2025. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was selected without a set-aside designation. This delivery order represents a single transaction under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the Defense Logistics Agency, a $499.999 billion master agreement valid through November 2026 that enables the agency to issue firm fixed-price orders for comprehensive pharmaceutical products supporting military health facilities worldwide.
As a critical supplier within the federal pharmaceutical supply chain, DMS Pharmaceutical Group specializes in delivering branded and generic prescription drugs, biologics, and medical consumables to Department of Defense healthcare sites. XTANDI is an oncology medication used in cancer treatment, consistent with the company's portfolio of specialized pharmaceutical products spanning injections, tablets, auto-injectors, and other medical supplies. The company's sustained contract awards with the Defense Logistics Agency demonstrate its established capability to meet federal pharmaceutical procurement requirements for military and federal healthcare systems nationwide.
Quick answers
Who was awarded contract SPE2DB25FZQ13?
SPE2DB25FZQ13 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on September 8, 2025.
How much is contract SPE2DB25FZQ13 worth?
The government has obligated $4,170 on SPE2DB25FZQ13.
Is contract SPE2DB25FZQ13 an order under another contract?
Yes. SPE2DB25FZQ13 is a delivery order under SPE2DB22D9102, an indefinite delivery contract.
Was contract SPE2DB25FZQ13 competed?
The extent of competition for SPE2DB25FZQ13 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award